Last reviewed · How we verify
Sodium Bicarbonate Powder and ondansetron
This combination uses sodium bicarbonate to neutralize gastric acid and ondansetron to block serotonin receptors and prevent nausea and vomiting.
This combination uses sodium bicarbonate to neutralize gastric acid and ondansetron to block serotonin receptors and prevent nausea and vomiting. Used for Nausea and vomiting associated with gastric acid reflux, Post-operative nausea and vomiting, Chemotherapy-induced nausea and vomiting.
At a glance
| Generic name | Sodium Bicarbonate Powder and ondansetron |
|---|---|
| Sponsor | Aya Sabry Mohamed Mohamed |
| Drug class | Antacid and antiemetic combination |
| Target | 5-HT3 receptor (ondansetron); non-specific acid neutralization (sodium bicarbonate) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Sodium bicarbonate acts as an antacid by neutralizing hydrochloric acid in the stomach, raising gastric pH and reducing acid-related symptoms. Ondansetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract, preventing nausea and vomiting from various causes including chemotherapy, post-operative states, and gastric irritation.
Approved indications
- Nausea and vomiting associated with gastric acid reflux
- Post-operative nausea and vomiting
- Chemotherapy-induced nausea and vomiting
Common side effects
- Headache
- Constipation
- Diarrhea
- Abdominal pain
- Metabolic alkalosis (sodium bicarbonate)
Key clinical trials
- The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity (PHASE3)
- Assessing The Role Of Intravenous Lipid Emulsion As A Life Saving Therapy In Pesticides Toxicity (PHASE4)
- Effectiveness of N-acetyl Cysteine, Acetyl L- Carnitine and Medicated Paraffin Oil in Aluminium Phosphide Poisoning (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: